Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
03.03.26
/
50%
€11.99
Target price
03.03.27
€41.04
Performance (%)
-20.23%
Price
28.07.26
€9.56
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -20.23%. This prediction currently runs until 03.03.27. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -4.970% | -4.970% |
| iShares Core DAX® | 1.717% | 3.368% |
| iShares Nasdaq 100 | -4.565% | -4.238% |
| iShares Nikkei 225® | -7.120% | -11.869% |
| iShares S&P 500 | -0.894% | 1.687% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Canaccord_Genuity_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.80
16.06.26
16.06.26
€42.31
16.06.27
16.06.27
-18.98%
28.07.26
28.07.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.66
28.04.26
28.04.26
€49.51
28.04.27
28.04.27
-18.01%
28.07.26
28.07.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€33.50
13.04.23
13.04.23
€59.72
13.04.24
13.04.24
-29.85%
14.04.24
14.04.24